Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Average Price Target from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $53.80.

Several research analysts recently weighed in on the company. Scotiabank upped their price target on Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a research report on Tuesday. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday.

Insider Buying and Selling

In other news, COO Patrick John Finn sold 10,340 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares in the company, valued at $10,610,928. The trade was a 4.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,002 shares of company stock valued at $2,851,681 in the last three months. Insiders own 3.01% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the third quarter worth $34,000. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the period. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after buying an additional 306 shares in the last quarter. US Bancorp DE raised its stake in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $95,000.

Twist Bioscience Trading Up 3.2 %

TWST traded up $1.64 during trading on Friday, reaching $53.66. 942,523 shares of the company were exchanged, compared to its average volume of 781,392. The stock has a market cap of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.87. The firm has a 50 day moving average of $48.74 and a 200 day moving average of $46.27. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. The company's revenue was up 24.1% on a year-over-year basis. As a group, analysts forecast that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.